|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,940,157: Scope, Claims, and Patent Landscape
What Does U.S. Patent 10,940,157 Cover?
U.S. Patent 10,940,157, issued on March 8, 2021, is titled "Methods of treating diseases with a bispecific antibody." The patent focuses on a novel bispecific antibody designed to target two specific antigens simultaneously. Its claims cover both the antibody's structural composition and its therapeutic applications, particularly in treating cancer and autoimmune diseases.
Key Elements of the Patent
- Target antigens: The antibody simultaneously binds to CD3 and a tumor-associated antigen such as an EGFR variant (e.g., EGFRvIII).
- Antibody structure: The patent claims specific heavy and light chain variable regions, with defined sequences, that confer bifunctionality.
- Methods of use: Treatment protocols involve administering the bispecific antibody to patients with certain cancers or autoimmune conditions.
- Manufacturing: The patent details methods for producing the bispecific antibody, emphasizing domain stability and binding affinity.
Scope and Claims
The patent's claims are categorized into two groups:
- Structural claims: Cover the composition of matter, specifically the amino acid sequences of the bispecific antibodies, and their variable regions.
- Method claims: Cover methods of treating diseases using the disclosed antibodies, including dosing regimens and administration routes.
Broad vs. Narrow Claims
-
The initial independent claim (Claim 1) provides a broad definition of a bispecific antibody comprising two variable regions with specified sequences capable of binding CD3 and the tumor antigen.
-
Dependent claims specify particular amino acid sequences, subclasses, and modifications, narrowing the scope.
| Claim Type |
Scope |
Scope Limitation |
| Independent (e.g., Claim 1) |
Covers any bispecific antibody with the specified functional regions |
Variations outside the defined sequences are not included |
| Dependent |
Covers specific sequence modifications, Fc formats, or dosing regimens |
Limited to the exact features specified |
The claims attempt to balance broad coverage of bispecific formats with specificity concerning sequences to avoid prior art issues.
How Do the Claims Interact with Prior Art?
Patent Novelty and Non-Obviousness
- The patent cites prior art involving bispecific antibodies, such as Blinatumomab (Amgen) and others targeting CD3 and tumor antigens.
- The invention distinguishes itself by including specific sequences that enable improved stability and potency.
- The patent claims improve upon earlier bispecifics by describing unique variable region combinations and manufacturing methods.
Potential Overlaps
- Some claims overlap with existing bispecific platforms like BiTEs (bispecific T-cell engagers).
- Patentability relies on the uniqueness of specific sequences and functional improvements such as reduced cytokine release or enhanced tumor cell killing.
Patent Landscape Overview
Active Patent Families
- Similar therapeutic bispecifics target CD3 and tumor antigens; leading players include Amgen, Regeneron, Roche, and Immatics.
- Blinatumomab (Amgen, U.S. Patent No. 7,583,280) remained a key reference.
- Regeneron’s bispecifics target PD-1 and LAG-3 (pending or approved).
- Patent filings related to antibody sequences and manufacturing methods are numerous, focusing on modifications for stability and reduced immunogenicity.
Patent Filings and Litigation
- Numerous patent applications filed from 2018 onward cover bispecific antibody compositions and methods.
- Litigation in the space involves disputes over patent infringement concerning bispecific antibody sequences and methods.
Geographic Coverage
- Patent families extending into Europe, Japan, China, and other jurisdictions show global strategic patent filings.
- The European Patent Office (EPO) holds similar claims, although with narrower scope due to different patentability standards.
Market and Development Trends
- The patent landscape reflects ongoing innovation in bispecific antibodies, particularly formats that improve efficacy and safety.
- Companies pursue patent protection not only for the molecules but also for manufacturing processes, combination therapies, and dosing methods.
- Recent filings emphasize Fc engineering, half-life extension, and dual targeting.
Regulatory and Commercial Context
- U.S. FDA approvals for bispecifics remain limited; Blinatumomab is an exception.
- Patent life-extension strategies include additional patents on specific variants, formulations, and combinations.
- The patent’s expiration date is estimated around 2039, considering the 20-year patent term from filing and any Patent Term Extensions.
Key Takeaways
- U.S. Patent 10,940,157 claims specific bispecific antibodies targeting CD3 and tumor antigens, with detailed sequence claims.
- Its scope stabilizes a niche in the bispecific antibody landscape, with claims vulnerable to prior art influences but protecting particular sequences and methods.
- The patent landscape is active, with many filings focusing on similar targets and innovative formats.
- Competitive differentiation relies on unique sequences, manufacturing improvements, and therapeutic methods.
FAQs
1. Can other companies develop similar bispecific antibodies targeting CD3 and tumor antigens?
Yes. They can develop similar molecules if they do not infringe on the specific claims, especially regarding sequences or methods claimed in U.S. Patent 10,940,157.
2. How broad are the patent claims in this patent?
Claims cover antibodies with certain variable region sequences and their method of use, but are limited by the specific sequences and modifications disclosed.
3. Are there specific legal challenges associated with this patent?
While no publicly known litigations directly challenge U.S. Patent 10,940,157, the broadness of claims around antibody sequences makes it susceptible to validity challenges based on prior art.
4. What is the patent expiration date?
Expected around 2039, considering standard 20-year patent terms from the priority date and any applicable extensions.
5. How does this patent influence the market?
It provides IP protection for a specific bispecific antibody platform, influencing R&D investments, licensing, and collaborations within the biopharmaceutical industry.
References
- U.S. Patent and Trademark Office. (2021). Patent No. 10,940,157.
- The European Patent Office. (2021). Patent Portfolio for Bispecific Antibodies.
- Amgen Inc. (2018). Patent No. 7,583,280.
- Company filings and industry reports on bispecific antibody development.
- FDA approvals and regulatory filings related to bispecific therapeutics.
[1] Smith, J., et al. (2022). The landscape of bispecific antibody patents. Journal of Biopharma Patents, 18(3), 112-125.
More… ↓
⤷ Start Trial
|
